• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bosentan Teva 62.5, 125 mg
    / Abic


    Active Ingredient
    Bosentan (as monohydrate) 62.5 mg, 125 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Coated Tablets

    Blisters: 60 (Tablets per pack) X 62.5 mg

    partial basket chart

    Coated Tablets

    Blisters: 60 (Tablets per pack) X 125 mg

    partial basket chart

    Dosage

    Please refer to the patient information leaflet for full details, unless instructed otherwise by the doctor.


    Indications

    Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV.
    Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.


    Contra-Indications

    Please refer to the patient information leaflet for full details. Please note that patient safety information card  is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.


    Special Precautions

    Please refer to the patient information leaflet for full details. Please note that patient safety information card  is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.


    Side Effects

    Please refer to the patient information leaflet for full details. Please note that patient safety information card  is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE